Palmitoyl Tripeptide-1

Overview

Palmitoyl Tripeptide-1 is a synthetic lipopeptide consisting of the tripeptide sequence GHK (glycine-histidine-lysine) conjugated to a palmitic acid chain at its N-terminus. Developed by Sederma as a cosmetic peptide active ingredient, it functions as a matrikine — a bioactive extracellular matrix fragment that signals cells to synthesize new structural proteins. The compound is the lipophilic derivative of the same GHK sequence that forms the basis of the naturally occurring GHK-Cu copper peptide complex.

Palmitoyl Tripeptide-1 is best known as one half of the Matrixyl 3000 formulation, where it is combined with Palmitoyl Pentapeptide-4 (Matrixyl) to provide a dual-matrikine approach to collagen stimulation. While Matrixyl delivers the KTTKS procollagen fragment signal, Palmitoyl Tripeptide-1 delivers the GHK matrikine signal, activating a complementary set of ECM synthesis pathways through TGF-beta-mediated mechanisms.

The palmitoylation strategy mirrors that employed for Matrixyl: the C16 fatty acid chain enhances the peptide's lipophilicity, improving penetration through the stratum corneum to reach target fibroblasts in the dermis via topical application. Without the palmitoyl modification, the hydrophilic GHK tripeptide has limited ability to cross the skin barrier at cosmetically relevant concentrations.

Palmitoyl Tripeptide-1 was previously marketed under the trade name Biopeptide-CL and the INCI designation Palmitoyl Oligopeptide before nomenclature standardization.

Structure

Palmitoyl Tripeptide-1 is a palmitoylated derivative of the GHK tripeptide:

Sequence: Pal-Gly-His-Lys

• Molecular formula: C₃₀H₅₄N₆O₅
• Molecular weight: 578.79 g/mol
• CAS Number: 147732-56-7
• INCI name: Palmitoyl Tripeptide-1
• Origin: Synthetic (peptide synthesis); GHK sequence is naturally occurring in human plasma and ECM degradation products

The GHK sequence was identified as a matrikine fragment of type I collagen and other ECM proteins. In its natural context, GHK is released during collagen turnover and acts as a feedback signal to fibroblasts, stimulating production of replacement matrix components. The palmitoyl modification converts this water-soluble signaling peptide into an amphiphilic molecule capable of skin penetration.

Unlike GHK-Cu, Palmitoyl Tripeptide-1 is not formulated with a copper ion. The palmitoyl chain occupies the N-terminal amino group that would otherwise participate in copper coordination, so the two derivatives represent distinct exploitations of the same peptide sequence — one as a metallopeptide copper delivery system, the other as a lipopeptide skin-penetrating matrikine.

Mechanism of Action

TGF-beta Signaling Activation

The primary mechanism attributed to Palmitoyl Tripeptide-1 is activation of the transforming growth factor-beta (TGF-beta) signaling pathway. Upon reaching dermal fibroblasts, the GHK sequence is recognized by cell surface receptors that trigger TGF-beta release and downstream signaling:

1. TGF-beta activation — the peptide stimulates release and activation of latent TGF-beta from fibroblast stores
2. Smad phosphorylation — activated TGF-beta receptors phosphorylate Smad2 and Smad3 transcription factors
3. Nuclear translocation — phosphorylated Smads form complexes with Smad4 and translocate to the nucleus
4. Gene transcription — Smad complexes drive expression of genes encoding collagen I, collagen III, elastin, fibronectin, and glycosaminoglycans

Extracellular Matrix Synthesis

The downstream effects of TGF-beta pathway activation by Palmitoyl Tripeptide-1 include upregulation of:

• Collagen types I and III — the predominant structural collagens of the dermis
• Elastin — responsible for skin snap-back and resilience
• Fibronectin — a glycoprotein essential for cell-ECM adhesion and tissue organization
• Glycosaminoglycans (GAGs) — including hyaluronic acid, which provides dermal hydration and volume
• Tissue inhibitors of metalloproteinases (TIMPs) — which protect newly synthesized ECM from premature degradation

Synergy with KTTKS (Matrixyl 3000)

The combination of Palmitoyl Tripeptide-1 with Matrixyl in the Matrixyl 3000 formulation is based on the principle that the GHK and KTTKS matrikine signals activate overlapping but not identical gene expression programs. GHK-mediated signaling emphasizes TGF-beta-driven collagen and elastin synthesis, while KTTKS signaling has stronger effects on collagen I transcription and fibronectin production. Together, they provide broader ECM stimulation than either peptide alone.

Comparison with GHK-Cu

While both Palmitoyl Tripeptide-1 and GHK-Cu deliver the GHK matrikine signal, their secondary mechanisms differ:

Research Summary

Applications

Matrixyl 3000 System

The primary commercial application of Palmitoyl Tripeptide-1 is within the Matrixyl 3000 blend, where it is co-formulated with Matrixyl (Pal-KTTKS). This combination has become one of the most widely used peptide systems in anti-aging skincare, found in products ranging from mass-market moisturizers to professional-grade serums.

Typical formulation concentrations are 2-5% of the Matrixyl 3000 commercial solution. The dual-peptide system is compatible with standard cosmetic matrices and can be combined with complementary actives including retinoids, niacinamide, hyaluronic acid, and vitamin C derivatives.

Standalone Formulations

Palmitoyl Tripeptide-1 is also available as a standalone ingredient (marketed as Biopeptide-CL) for formulations where the GHK-mediated TGF-beta stimulation is the desired primary mechanism. Standalone use is less common than the Matrixyl 3000 combination but occurs in bespoke professional formulations and custom compounding.

Post-Procedure Support

Like other collagen-stimulating peptides, Palmitoyl Tripeptide-1-containing formulations are used in post-procedure protocols following:

• Laser skin resurfacing
• Chemical peels
• Microneedling treatments
• Fractional radiofrequency procedures

The rationale is that augmenting the body's natural wound healing collagen synthesis with exogenous matrikine signals may enhance the neocollagenesis that produces the cosmetic benefit of these procedures.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Palmitoyl Tripeptide-1 (Pal-GHK / Biopeptide-CL) is a topical cosmetic peptide.

Application notes: Most commonly used in combination with Matrixyl (Pal-KTTKS) as the Matrixyl 3000 blend. Apply to clean skin before moisturizer. Consistent use for 4-8 weeks is generally recommended before evaluating results. Compatible with retinoids, vitamin C, and other active ingredients when used at different times of day.

Related Compounds

• Matrixyl — Palmitoyl Pentapeptide-4 (Pal-KTTKS), the other component of Matrixyl 3000; delivers a complementary procollagen-derived matrikine signal
• GHK-Cu — the copper-complexed form of the same GHK sequence, delivering additional metalloenzyme-activating and broad gene-modulatory effects
• Copper Peptides — the broader class of copper-binding peptides to which GHK-Cu belongs
• Argireline — a neuromuscular peptide addressing dynamic expression lines; complementary to the structural ECM approach of Palmitoyl Tripeptide-1
• Palmitoyl Tripeptide-38 — the active in Sederma's Matrixyl Synthe'6, stimulating six dermal-epidermal junction components